Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

ABSTRACT:

Objective

We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess the safety of this strategy.

Methods

Patients with untreated stage I-IIIA non-small cell lung cancer underwent neoadjuvant therapy with 2 cycles of nivolumab (3 mg/kg), 4 and 2 weeks before resection. Patients underwent invasive mediastinal staging as indicated and post-treatment computed tomography. Primary study end points were safety and feasibility of neoadjuvant nivolumab followed by pulmonary resection. Data on additional surgical details were collected through chart review.

Results

Of 22 patients enrolled, 20 underwen

SUBMITTER: Bott MJ 

PROVIDER: S-EPMC6653596 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature